| Previous Close | 8.61 |
| Open | 9.00 |
| Bid | 8.63 x 0 |
| Ask | 9.13 x 0 |
| Day's Range | 8.47 - 9.00 |
| 52 Week Range | 4.35 - 11.03 |
| Volume | 920 |
| Avg. Volume | 1,082 |
| Market Cap | 171.303M |
| Beta (5Y Monthly) | 0.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.64 |
| Earnings Date | Mar. 28, 2018 - Apr. 01, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Announced that the U.S. Patent and Trademark Office will issue U.S. Patent 10,596,190 entitled “Method ...
RESEARCH TRIANGLE PARK, N.C., March 05, 2020 -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of.
Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the company’s Marketing Authorization Application (MAA) for its investigational drug, sodium thiosulfate (unique formulation) for infusion (tradename to be determined in EU), has passed validation and is now under evaluation by the European Medicines Agency (EMA). The MAA for Pediatric Use Marketing Authorization (PUMA) was filed in early February 2020 for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to
NDA (New Drug Application) and Marketing Authorization Application (MAA) completed in February 2020Commercial readiness activities in U.S. underway for potential launch of.
Fennec Pharmaceuticals Inc. (Nasdaq:FENC; TSX: FRX), a specialty pharmaceutical company, today announced it has completed its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PEDMARK™ (a unique formulation of sodium thiosulfate) for intravenous use and submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for sodium thiosulfate (tradename to be determined). The PEDMARK™ indication requested is for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to
NDA (New Drug Application) for PEDMARKTM to be completed in early 2020Strong financial position with $15.2 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Nov. 12,.
RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2019 -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM.
TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that it has appointed Jodi A. Cook, PhD to its board of directors. Dr. Cook currently serves as Head of Gene Therapy Strategy at PTC Therapeutics, Inc., a global biopharmaceutical company focused on the development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders.
TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that it has appointed Shubh Goel as chief commercial officer. In this newly created position, Ms. Goel will build and oversee Fennec’s commercial strategy and organization, including the launch and commercialization of PEDMARK™, if approved. “I am thrilled to join Fennec at such a transformative moment, as we prepare for the potential commercial launch of PEDMARK,” said Ms. Goel.
Anticipate PEDMARK™ New Drug Application (NDA) completion by early 2020Strong financial position with $17.5 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Aug. 09,.
RESEARCH TRIANGLE PARK, N.C., June 19, 2019 -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management.
Targeting New Drug Application to U.S. FDA for PEDMARKTM in late 2019 to early 2020Strong financial position with $20.2 million in cash and no debt RESEARCH TRIANGLE PARK,.